The Federal Trade Commission has approved Cardinal Health’s application to sell Patient Care Infusion. The 4-0-1 approval comes after a public comment period. Cardinal Health’s divestment is part of a 2011 FTC settlement to resolve competition issues with its acquisition of three nuclear pharmacies from Biotech. Patient Care Infusion has the capacity and ability to operate reconstituted nuclear pharmacies that Cardinal had closed after completing its acquisition. The pharmacies are in Las Vegas, Albuquerque, and El Paso.
Full content: FTC Press Release
Related content: Observations on the Commission’s Evanston Remedy: When Is Divestiture, or Any Remedy, Not Appropriate for a Consummated Anticompetitive Merger? (Mark Botti, Akin Gump)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.